The need for quadrivalent vaccine against seasonal influenza

被引:161
|
作者
Belshe, Robert B. [1 ]
机构
[1] St Louis Univ, Sch Med, Div Infect Dis & Immunol, St Louis, MO 63103 USA
关键词
Influenza; Influenza B infection; Seasonal influenza; Quadrivalent vaccine; B VIRUS-INFECTIONS;
D O I
10.1016/j.vaccine.2010.08.028
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Seasonal influenza epidemics represent a substantial public health burden, causing significant morbidity and mortality. Influenza in humans can be caused by influenza type A and type B viruses, and although influenza A is responsible for the majority of seasonal influenza infections, influenza B disease is common in children and young adults, and causes seasonal epidemics every 2-4 years. Influenza strains circulating during a seasonal epidemic may be influenza type A strains A/H1N1 and A/H3N2, strains of influenza B lineages B/Victoria and B/Yamagata, or any combination of these. The morbidity and mortality burden of influenza infections means that public health agencies worldwide recommend vaccination to try and protect against seasonal epidemics. The World Health Organization (WHO) and, in the United States of America (USA), the Food and Drug Administration (FDA), recommend trivalent seasonal influenza vaccines containing the two main influenza type A strains and, due to its lesser but still important prevalence, one influenza type B strain. There is little or no cross-reactive protection between the influenza B lineages: this means that good protection against the circulating virus relies on correctly predicting the prevalent influenza B lineage in any season. This has proved to be reliant on chance, and little or no protection has been provided in the USA by the trivalent vaccines against the circulating influenza B virus in 5 of the 10 seasons between 2001 and 2010. There is, therefore, a clear need for a quadrivalent influenza vaccine, containing influenza A/H1N1, A/H3N2, and B/Victoria and B/Yamagata lineage strains, to improve protection against influenza B virus and reduce the morbidity of influenza B infection. (c) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:D45 / D53
页数:9
相关论文
共 50 条
  • [21] Cost-Effectiveness of the Use of Adjuvanted Quadrivalent Seasonal Influenza Vaccine in Older Adults in Ireland
    Nguyen, Van Hung
    Ashraf, Mansoor
    Mould-Quevedo, Joaquin F. F.
    VACCINES, 2023, 11 (05)
  • [23] Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina
    Uruena, Analia
    Micone, Paula
    Magneres, Cecilia
    Mould-Quevedo, Joaquin
    Giglio, Norberto
    VACCINES, 2021, 9 (04)
  • [25] Influenza seasonal vaccine
    不详
    AUSTRALIAN PRESCRIBER, 2009, 32 (06) : 168 - 168
  • [26] An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population
    Fochesato, Anna
    Sottile, Sara
    Pugliese, Andrea
    Marquez-Pelaez, Sergio
    Toro-Diaz, Hector
    Gani, Ray
    Alvarez, Piedad
    Ruiz-Aragon, Jesus
    VACCINES, 2022, 10 (08)
  • [27] Effectiveness of Cell-Based Quadrivalent Seasonal Influenza Vaccine: A Systematic Review and Meta-Analysis
    Coleman, Brenda L.
    Gutmanis, Iris
    Mcgovern, Ian
    Haag, Mendel
    VACCINES, 2023, 11 (10)
  • [28] COST EFFECTIVENESS OF QUADRIVALENT INFLUENZA VACCINE OVER TRIVALENT VACCINE IN FRANCE
    Duru, G.
    Carrat, F.
    Pribil, C.
    Bricaire, F.
    Pujol, P.
    Robert, J.
    Lafuma, A.
    VALUE IN HEALTH, 2014, 17 (07) : A678 - A678
  • [29] THE ANTIBODY RESPONSE IN MAN TO A QUADRIVALENT INFLUENZA VIRUS VACCINE
    BUCHNER, BK
    REID, DBW
    DEMPSTER, G
    CANADIAN JOURNAL OF MICROBIOLOGY, 1955, 1 (04) : 249 - 255
  • [30] Mosaic quadrivalent influenza vaccine single nanoparticle characterization
    Yang, Rong Sylvie
    Traver, Maria
    Barefoot, Nathan
    Stephens, Tyler
    Alabanza, Casper
    Manzella-Lapeira, Javier
    Zou, Guozhang
    Wolff, Jeremy
    Li, Yile
    Resto, Melissa
    Shadrick, William
    Yang, Yanhong
    Ivleva, Vera B.
    Tsybovsky, Yaroslav
    Carlton, Kevin
    Brzostowski, Joseph
    Gall, Jason G.
    Lei, Q. Paula
    SCIENTIFIC REPORTS, 2024, 14 (01)